Roche granted TeaRx exclusive rights to develop and commercialize preclinical oral Factor Xa inhibitors in Russia and 11 other undisclosed countries

Roche

Switzerland / Large-Cap Biopharma (>=$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

TeaRx LLC

Russia / Private Biopharma

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced